Shepard has spent nearly two decades at the intersection of health care and investments. Most recently, he served as vice president of business development and program management within the biotechnology industry at Astonishing Labs and Aether Therapeutics. Prior to that, Shepard was a Partner at Endurant Capital Management, where he spent nine years investing in pharmaceutical, biotechnology and specialty pharmaceutical equities across therapeutic areas including autoimmune disease, oncology, rare disease and genetic medicine. Earlier in his career, Shepard held equity research roles at Credit Suisse, Bank of America Merrill Lynch, and Pacific Growth Equities/Wedbush Securities, where he supported coverage of biotechnology companies and helped lead numerous IPOs and follow-on offerings. He began his career as a licensing liaison in Stanford University’s Office of Technology Licensing, where he helped manage licensing agreements for biotechnology and medical device inventions.